Status:
TERMINATED
An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data
Lead Sponsor:
XOMA (US) LLC
Conditions:
Uveitis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to provide continued dosing of gevokizumab in order to obtain and assess long-term gevokizumab safety data.
Eligibility Criteria
Inclusion
- Completed either the X052130/CL3-78989-005 or the X052131/CL3-78989-006 study's masked D392 or OL-224 completion day visits or had controlled ocular inflammation after having received study drug in Part 2 of study X052133
Exclusion
- Discontinued from the previous study
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
March 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2017
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT02258854
Start Date
March 1 2014
End Date
December 1 2017
Last Update
October 16 2015
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Chandler, Arizona, United States
2
Phoenix, Arizona, United States
3
Beverly Hills, California, United States
4
Redlands, California, United States